WO2003012082A3 - Methode destinee a la modulation de la differenciation de cellules-souche, utilisant de l'arn a structure tige-boucle - Google Patents

Methode destinee a la modulation de la differenciation de cellules-souche, utilisant de l'arn a structure tige-boucle Download PDF

Info

Publication number
WO2003012082A3
WO2003012082A3 PCT/GB2002/003409 GB0203409W WO03012082A3 WO 2003012082 A3 WO2003012082 A3 WO 2003012082A3 GB 0203409 W GB0203409 W GB 0203409W WO 03012082 A3 WO03012082 A3 WO 03012082A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem
cell differentiation
modulating
loop rna
stem cell
Prior art date
Application number
PCT/GB2002/003409
Other languages
English (en)
Other versions
WO2003012082A2 (fr
Inventor
Peter Andrews
James Walsh
Paul Gokhale
Original Assignee
Axordia Ltd
Peter Andrews
James Walsh
Paul Gokhale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axordia Ltd, Peter Andrews, James Walsh, Paul Gokhale filed Critical Axordia Ltd
Publication of WO2003012082A2 publication Critical patent/WO2003012082A2/fr
Publication of WO2003012082A3 publication Critical patent/WO2003012082A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode permettant de promouvoir la différenciation de cellules-souche, en particulier de cellules-souche embryonnaires, par interférence de l'ARN induite par introduction d'ARN à structure tige-boucle dans une cellule.
PCT/GB2002/003409 2001-07-26 2002-07-25 Methode destinee a la modulation de la differenciation de cellules-souche, utilisant de l'arn a structure tige-boucle WO2003012082A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0118223.7 2001-07-26
GB0118223A GB0118223D0 (en) 2001-07-26 2001-07-26 Stem loop RNA

Publications (2)

Publication Number Publication Date
WO2003012082A2 WO2003012082A2 (fr) 2003-02-13
WO2003012082A3 true WO2003012082A3 (fr) 2004-06-10

Family

ID=9919226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/003409 WO2003012082A2 (fr) 2001-07-26 2002-07-25 Methode destinee a la modulation de la differenciation de cellules-souche, utilisant de l'arn a structure tige-boucle

Country Status (2)

Country Link
GB (1) GB0118223D0 (fr)
WO (1) WO2003012082A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
IL159756A0 (en) 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
GB0307206D0 (en) * 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
WO2005115439A2 (fr) 2004-05-27 2005-12-08 Acceleron Pharma Inc. Derives de cerberus/coco et leurs applications
US9045553B2 (en) 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
GB0501129D0 (en) * 2005-01-19 2005-02-23 Ribostem Ltd Method of treatment by administration of RNA
EP2099471A2 (fr) 2006-12-08 2009-09-16 Acceleron Pharma, Inc. Utilisations de cerberus, de coco et de leurs dérivés
EP3877748A4 (fr) * 2018-11-06 2022-11-09 Cellino Biotech, Inc. Systèmes de contrôle de cellules

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045143A1 (fr) * 1996-05-31 1997-12-04 The National American Red Cross Procedes et compositions therapeutiques et diagnostiques obtenues a partir de proteines jagged/notch et d'acides nucleiques
WO1998058958A2 (fr) * 1997-06-25 1998-12-30 University Of Washington Polypeptide jagged humain, acides nucleiques codants et procedes d'utilisation
WO1999032619A1 (fr) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
WO2000025809A1 (fr) * 1998-10-30 2000-05-11 Smith & Nephew Plc Compositions contenant des agents actifs sur les recepteurs notch
WO2000063364A2 (fr) * 1999-04-21 2000-10-26 American Home Products Corporation Procedes et compositions pour l'inhibition de la fonction de sequences polynucleotidiques
WO2001003743A1 (fr) * 1999-07-12 2001-01-18 Walter Gehring Manipulation de type de tissu ou d'organe par utilisation de la voie notch
WO2001025422A2 (fr) * 1999-10-07 2001-04-12 Avi Biopharma, Inc. Compositions antisens et methodes de traitement du cancer
WO2001036646A1 (fr) * 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2002016620A2 (fr) * 2000-08-19 2002-02-28 Axordia Limited Differenciation de cellule es

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045143A1 (fr) * 1996-05-31 1997-12-04 The National American Red Cross Procedes et compositions therapeutiques et diagnostiques obtenues a partir de proteines jagged/notch et d'acides nucleiques
WO1998058958A2 (fr) * 1997-06-25 1998-12-30 University Of Washington Polypeptide jagged humain, acides nucleiques codants et procedes d'utilisation
WO1999032619A1 (fr) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
WO2000025809A1 (fr) * 1998-10-30 2000-05-11 Smith & Nephew Plc Compositions contenant des agents actifs sur les recepteurs notch
WO2000063364A2 (fr) * 1999-04-21 2000-10-26 American Home Products Corporation Procedes et compositions pour l'inhibition de la fonction de sequences polynucleotidiques
WO2001003743A1 (fr) * 1999-07-12 2001-01-18 Walter Gehring Manipulation de type de tissu ou d'organe par utilisation de la voie notch
WO2001025422A2 (fr) * 1999-10-07 2001-04-12 Avi Biopharma, Inc. Compositions antisens et methodes de traitement du cancer
WO2001036646A1 (fr) * 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2002016620A2 (fr) * 2000-08-19 2002-02-28 Axordia Limited Differenciation de cellule es

Also Published As

Publication number Publication date
GB0118223D0 (en) 2001-09-19
WO2003012082A2 (fr) 2003-02-13

Similar Documents

Publication Publication Date Title
WO2003012082A3 (fr) Methode destinee a la modulation de la differenciation de cellules-souche, utilisant de l'arn a structure tige-boucle
AU2002211317A1 (en) Methods and compositions for directed microwave chemistry
EP1572984B8 (fr) Système de culture pour cellules souches embryonnaires humaines sans cellules nourricieres ni composants xénogènes
WO2001034835A3 (fr) Procede de production de biopolymeres a proprietes modifiees
WO2003062375A3 (fr) Stabilisation de polypeptides exposes à l'uree
WO2002018617A3 (fr) Production de carotenoides a partir d'un substrat de carbone simple
EP1180371A4 (fr) Agents favorisant la formation d'une membrane de base de la peau, agents favorisant la formation d'une peau artificielle et procede de production de peau artificielle
WO2003000038A3 (fr) Compositions et procedes de modulation du developpement de plantes
WO2002057783A3 (fr) Methodes de criblage de ligands gpr40
WO2001092473A3 (fr) Cartilage artificiel et procedes permettant de le produire
AU2002321292A1 (en) Hybrid membrane, method for the production thereof and use of said membrane
WO2004087735A3 (fr) Anticorps proteolytiques et covalents
HK1056292A1 (en) Method of culturing zooplankton, apparatus for culturing by the same, and culture obtained by the same.
ZA200007458B (en) Method of preparing a fuel cell.
ZA200106158B (en) Method for production of catalyst.
WO2003002521A3 (fr) Procede de preparation de composes type azoique
WO2003035886A3 (fr) Preparation d'heparine a partir de cultures de mastocytes
WO2005060721A3 (fr) Manipulation de l'interference arn par modulation de l'activite du gene armitage
ZA200106159B (en) Method for production of catalyst.
AU2002225011A1 (en) Method for improving the water balance of fuel cells
AU2001258400A1 (en) Method for introducing a nucleic acid into a cell (transfection) by means of calcium phosphate, and transfected cell
AU2002355785A1 (en) Method for modulating stem cell differentiation using stem loop rna
HUP0402020A3 (en) A process for preparation of the 14beta-hydroxy-baccatin iii-1,14-carbonate
AU2003284815A1 (en) Method for conversion of waveguide modes, mode-converting arrangement and antenna arrangement.
WO2000068234A3 (fr) Preparation d'acide de cefpodoxime

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP